Seasoned biopharmaceutical industry professional with progressive expertise across the full clinical development lifecycle (Phases I–IV), spanning site management, clinical trial execution, oversight, and inspection readiness. Deeply experienced in GCP, ICH E6, Health Canada Division 5, and FDA regulatory frameworks.

My work centers on the oversight of TMF completeness, site performance, and deviation management, with a strong emphasis on ensuring studies are not only inspection-ready but operationally resilient and defensible under regulatory scrutiny.

I am particularly interested in how clinical operations continue to evolve in increasingly complex trial environments, and how organizations can strengthen consistency, oversight, and execution across studies.

More broadly, I reflect on how different aspects of trial conduct come together to shape overall study quality and readiness.

I am always open to engaging with peers and industry leaders on clinical operations, quality strategy, and innovation in trial execution.

• Atrial Fibrillation (device)
• Heart Failure
• Hypertension
• Sarcoidosis Associated Pulmonary Hypertension

• Atopic Dermatitis
• Psoriasis

• Crohn's Disease
• Dyslipidemia
• Diabetes
• Hepatitis C
• Irritable Bowel Syndrome (IBS)
• Obesity
• Ulcerative Colitis

• Acquired Hemophilia

• Huntington's Disease
• Parkinson's Disease

• Bladder Cancer
• Breast Cancer 
• Chronic Lymphocytic Lymphoma (CLL)
• Colorectal Cancer
• Multiple Myeloma
• Non-Hodgkin Lymphoma
• Non-Small Cell Lung Cancer (NSCLC)
• Prostate Cancer

• Duchenne Myelopathy

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Respiratory Syncytial Virus (RSV) Vaccine

• Ankylosing Spondylitis 
• Lupus
• Psoriatic Arthritis
• Rheumatoid Arthritis (pediatric and adult population)

• English (Native or Bilingual Proficiency)
• French (Native or Bilingual Proficiency)
• Spanish (Professional Working Proficiency)
• German (Elementary Proficiency)